Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

On February 17, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Modification to the Methodology of the S&P ESG Leaders Indices

Modification to the Methodology of the S&P Carbon Control Index Series

MACOM Technology Solutions Holdings Set to Join S&P MidCap 400